Search

Displaying results 4461 - 4470 of 10000 in total
  1. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  2. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  3. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.

  4. Drug

    Biomed 101

    go.drugbank.com/drugs/DB05851
    Investigational

    Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid.

  5. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or

  6. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

  7. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  8. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]

  9. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    It is believed that similar effects would be seen in cells isolated from hypertrophic scars. … In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control.

  10. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    It reduces appetite and increases satiety in obese patients.